Frontiers in Immunology (Nov 2016)

Biomarker tools to design clinical vaccines determined from a study of annual listeriosis incidence in northern Spain

  • Ricardo Calderón González,
  • Hector Teran-Navarro,
  • Jose Maria Marimon,
  • Jose Maria Marimon,
  • Claudia Gonzalez-Rico,
  • Jorge Calvo-Montes,
  • Elisabet Frande Cabanes,
  • Miriam Alkorta-Gurrutxaga,
  • Miriam Alkorta-Gurrutxaga,
  • Carmen Fariñas,
  • Carmen Fariñas,
  • Luis Martinez-Martinez,
  • Luis Martinez-Martinez,
  • Emilio Perez-Trallero,
  • Emilio Perez-Trallero,
  • Carmen Alvarez-Dominguez

DOI
https://doi.org/10.3389/fimmu.2016.00541
Journal volume & issue
Vol. 7

Abstract

Read online

Two regions of northern Spain, Gipuzkoa and Cantabria present high annual incidence of listeriosis (1.86 and 1.71 cases per 100,000 inhabitants, respectively). We report that the high annual incidences are a consequence of infection with highly virulent L. monocytogenes isolates linked to fatal outcomes in elderly patients with cancer. In addition, listeriosis patients with cancer present low IL-17A/IL-6 ratios and significantly reduced levels of anti-GAPDH1-22 antibodies, identified as two novel biomarkers of poor prognosis. Analysis of these biomarkers may aid in reducing the incidence of listeriosis. Moreover, GAPDH1-22 activated monocyte derived dendritic cells of listeriosis patients with cancer seem useful tools to prepare clinical vaccines as they produce mainly Th1 cytokines.

Keywords